Paquet is a French national who since November 2015 has served as one of the three Deputy Secretaries-General of the Juncker Commission, and has now been been appointed as Director General of DG Research and Innovation
Mereo BioPharma Group plc, a multi-asset biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases, today announced the appointment of Wills Hughes-Wilson as Head of Patient Access and Commercial Planning.
Hikma Pharmaceuticals today announces its Board of Directors has appointed Sigurdur (Siggi) Olafsson as Chief Executive Officer. Mr Olafsson will also join Hikmas Board of Directors as an executive director, subject to election at the next annual general meeting in May 2018.
Addex Therapeutics, a leading company in allosteric modulation-based drug discovery and development, announced today the appointment of Jean-Philippe Rocher, PhD, as Co-Head of Discovery and Member of the Executive Management, effective 1 June 2018.
Selvita S.A., a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services, announced today the appointment of Steffen Heeger, M.D., PhD, to the role of Chief Medical Officer.
Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, today appointed Dr. Ralf Otto as Chief Operating Officer (COO), effective February 1, 2018.
Storm Therapeutics today announced the appointment of Nobel Prize Winner Professor Thomas Cech as a Scientific Advisor. This appointment follows STORM Therapeutics successful Series A Financing Extension announced in January 2018.
Congenica, a global provider of clinical genomics interpretation software, today announced the appointment of its new Chief Executive Officer David Atkins, Ph.D. Based at the Companys headquarters in Cambridge, UK, Dr Atkins also joins Congenicas Board of Directors.
BONESUPPORT (Nasdaq Stockholm: BONEX) announces that the Board of Directors has appointed Emil Billbäck as the new CEO of BONESUPPORT HOLDING AB. Mr. Billbäck has over 20 years management experience from the life science industry and the Board of Directors is of the opinion that he has the ideal profile to implement the Companys strategy and to deliver shareholder value. He will join BONESUPPPORT on 1st March 2018 when he will replace Richard Davies who has been the Companys CEO since January 2016.
Synpromics Ltd today announced the appointment of Sarah Haecker Meeks, PhD to the position of Vice President, Business Development.